Pressroom

 

Trending Topics

 

Check out the latest cancer-related news and also see who is readily available to offer reliable information, expert commentary, and reaction to today's headlines.
Contact a media coordinator

Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD, has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells, from self-destructing. During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness. The use of “genetic cloaking” prevents immune cell apoptosis, enhancing the effectiveness of cellular immunotherapies for liquid and solid cancers in mouse models. This new technique is also effective in protecting human cancer-fighting immune cells. These findings lay the groundwork for a potentially universal gene-engineering strategy to safely increase the potency of cellular immunotherapies for a broad range of cancers.
Tuesday, January 29, 2019
 
Doctors have had limited success developing targeted therapies for the treatment of glioblastoma and lower-grade glioma, the most common primary brain cancers in adults. Targeted therapy requires matching drugs to the genetic profile of a tumor, which can substantially change throughout the course of the disease. Keeping track of these changes is particularly challenging in people with brain tumors because collecting tumor DNA requires brain surgery. But experts from MSK have shown that utilizing the minimally invasive procedure commonly called a spinal tap may help doctors better understand a tumor’s changing genetic makeup, offering clues into such traits as tumor aggressiveness.
Wednesday, January 23, 2019
 
In patients with progressive, refractory, or symptomatic desmoid tumors, sorafenib (Nexavar®) significantly improved progression-free survival (PFS) and induced durable responses. This study defined an active therapy for desmoid tumors that appears effective in slowing disease progression.
Wednesday, December 19, 2018
 

See all trending topics Arrow rightAn icon showing an arrow pointing to the right.
 

Press Releases

 

Researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from a new study that looks at the likelihood of complications for people undergoing bone marrow transplants (BMTs). The observational study found that people with lower gut microbiota diversity before having a transplant appear to be at higher risk for developing complications. These findings further support evidence that the connection between microbiota and outcomes starts before people begin the transplantation process. These findings were presented as part of the 2018 annual meeting of the American Society of Hematology (ASH) press program.
Sunday, December 2, 2018
 
Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD, a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment, which is effective immediately, Dr. Cahlon will help oversee the network’s outpatient clinical programs, which span seven locations across New York and New Jersey.
Friday, November 23, 2018
 
Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune checkpoint blocker avelumab (Bavencio®) and the tyrosine kinase inhibitor (TKI) axitinib (Inlyta®) can significantly improve progression-free survival (PFS) in people who have been previously untreated for advanced renal cell carcinoma (RCC).
Sunday, October 21, 2018
 

See all press releases Arrow rightAn icon showing an arrow pointing to the right.
 

On Our Blog

 

MSK HEROES
In honor of Women’s History Month, meet the scientific hero who helped build MSK’s molecular biology program.
Wednesday, March 13, 2019
 
MSK HEROES
In honor of Women’s History Month, meet the scientific hero who helped raise money and awareness for AIDS research.
Wednesday, March 13, 2019
 
MSK HEROES
In honor of Women’s History Month, meet the scientific hero who shook up cancer research with her unusual findings.
Wednesday, March 13, 2019
 

See all blog posts Arrow rightAn icon showing an arrow pointing to the right.
 

Media Coverage

 

The treatments represent an emerging way of treating certain cancers—by targeting tumors based on their genetic characteristics, rather than their location in the body. MSK’s David Hyman is quoted.
Thursday, February 28, 2019
 
Young adults are increasingly developing colon cancer — and it’s often diagnosed at a late stage, after they’ve seen several doctors and been misdiagnosed, a new survey shows. MSK’s Robin Mendelsohn and Center for Young Onset Colorectal Cancer are highlighted.
Thursday, February 28, 2019
 
MSK’s Andrew Kung was a featured guest on C-SPAN’s Washington Journal and discussed breakthroughs in pediatric cancers and the need for additional funding.
Saturday, February 9, 2019
 

See all media coverage Arrow rightAn icon showing an arrow pointing to the right.
 

If you wish to contact MSK about a marketing or advertising related opportunity, or are looking for additional information about our ad campaign, please email us at marketing@mskcc.org.

For Journalists

Jeanne D'Agostino
Director, Media and Public Relations
 
Emily O'Donnell
Media Relations Manager, Surgery
 
Courtney Nowak
Media Relations Manager, Regional Care Network
 
Caitlin Hool
Senior Manager, Media Relations and Partnerships
 
Nicole H. McNamara
Senior Media Strategist
 
Rebecca Williams
Media Strategist
 
For press inquiries, our Media Staff are available by calling 646-227-3573 or by dialing the numbers above. Our office hours are Monday - Friday, 9:00 AM to 5:00 PM.
 
After hours, please contact the hospital's page operator at 212-639-7900 and ask for the Public Affairs representative on-call.

Live and Remote Broadcast Capabilities

Our experts can offer live broadcast interviews using the on-site studio system. To book an expert interview using our on-site broadcast studio contact our Media Staff.